Exclusive: CellFE raises $22M Series A to advance a new cell therapy manufacturing idea
The California-based startup CellFE has raised a $22 million Series A to advance a new approach to making cell therapies with microfluidics.
Most cell therapy developers use hollowed-out viruses to deliver the genetic edits that make cell therapies effective. But those viruses are expensive and difficult to manufacture and also limited in the size of what they can carry. CellFE CEO Alla Zamarayeva told Endpoints News that the company is trying a different approach by using tiny, microfluidic chips instead of viruses to modify cells.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.